by Usha Govindarajulu | Feb 17, 2022 | Biostatistics, Blog, COVID-19, Usha Govindarajulu
February 22, 2022 In a pre-print article published recently, the authors used life table and survival analyses methods to compare probability of dying from COVID-19 against probability of dying from other causes using data from the province Hubei of China, of which...
by Usha Govindarajulu | Feb 4, 2022 | Biostatistics, Blog, COVID-19, New York, Professor, Usha Govindarajulu
February 2, 2022 A recent article in the Lancet Infectious Diseases presents a large scale study of post-vaccination infection conducted in the United Kingdom to assess potential long-haul symptoms. It was a prospective, community-based, nested, case-control study...
by Usha Govindarajulu | Jan 7, 2022 | Biostatistics, Blog, COVID-19, Healtcare
January 5, 2022 With the ongoing rise in COVID-19 cases due to the Omicron variant of Sars-Cov-2, we searched for some actual studies on the change in vaccine efficacy due to Omicron exposure. In one pre-print article, Buchan et al studied 3,442...
by Usha Govindarajulu | Nov 26, 2021 | Biostatistics, Blog, COVID-19, Healtcare, Professor, Usha Govindarajulu
At home Antigen tests statistical results November 24, 2021 Antigen tests for SARS-CoV-2 are back and are pending more approvals by the current administration. If so, they may be used more often and more frequently to help people get back to a more normal lifestyle....
by Usha Govindarajulu | Nov 10, 2021 | Biostatistics, Blog, Healtcare, Usha Govindarajulu
Pfizer anti-viral November 10, 2021 Pfizer, similar to Merck, has announced the efficacy of their anti-viral drug called PAXLOVID against SARS-CoV-2. The reported 89% efficacy against serious disease and 100% efficacy against death and they are making headlines....
